benzyl (S)-4-(5-(5-bromo-3-(3-((tert-butyldiphenylsilyl)oxy)-2,2-dimethylpropyl)-1-ethyl-1H-indol-2-yl)-6-(1-methoxyethyl)pyridin-3-yl)piperazine-1-carboxylate (CAS No: 2641451-81-0) is a key pharmaceutical intermediate used in the synthesis of APIs Daraxonrasib. This compound serves as an essential raw material in API development and synthesis. Explore detailed chemical properties, molecular data, structure information, and verified global suppliers, manufacturers, and distributors of this API intermediate on apicule.
Alternate Names: 1-Piperazinecarboxylic acid, 4-[5-[5-bromo-3-[3-[[(1,1-dimethylethyl)diphenylsilyl]oxy]-2,2-dimethylpropyl]-1-ethyl-1H-indol-2-yl]-6-[(1S)-1-methoxyethyl]-3-pyridinyl]-, phenylmethyl ester
CAS No: 2641451-81-0
PubChem CID: 156678935
Mol Formula: C51H61BrN4O4Si
Mol Weight: 902.0 g/mol
Used in API: Daraxonrasib
IUPAC Name: benzyl 4-[5-[5-bromo-3-[3-[tert-butyl(diphenyl)silyl]oxy-2,2-dimethylpropyl]-1-ethylindol-2-yl]-6-[(1S)-1-methoxyethyl]-3-pyridinyl]piperazine-1-car -Show More
API Intermediate Description: Daraxonrasib (RMC-6236) is a RAS inhibitor, and benzyl (S)-4-(5-(5-bromo-3-(3-((tert-butyldiphenylsilyl)oxy)-2,2-dimethylpropyl)-1-ethyl-1H-indol-2-yl)-6-(1-methoxyethyl)pyridin-3-yl)piperazine-1-carboxylate is a highly advanced intermediate in its synthesis. It incorporates the key brominated indole–pyridine–piperazine framework, the protected dimethylpropyl alcohol (TBDPS ether), and the chiral methoxyethyl substituent required for the daraxonrasib structure. Subsequent cross-coupling, deprotection and functional-group transformations of this advanced intermediate lead toward the final daraxonrasib API.
